Ignite Creation Date:
2025-12-25 @ 3:28 AM
Ignite Modification Date:
2026-06-24 @ 12:52 PM
Study NCT ID:
NCT07080905
Status:
RECRUITING
Last Update Posted:
2025-12-17
First Post:
2025-07-07
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B
Sponsor:
CSL Behring
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CSL222_3004
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None